Ovid Therapeutics Inc. filed a Form S-3 registration statement with the Securities and Exchange Commission on November 10, 2026, covering up to $250,000,000 in securities and including a $75,000,000 at-the-market equity facility with Cantor Fitzgerald & Co.

Key Highlights

  • Base shelf size: Up to $250,000,000 of common stock, preferred stock, debt securities, and/or warrants may be offered from time to time in one or more offerings.
  • ATM facility: A sales agreement prospectus covers up to $75,000,000 of common stock under a Controlled Equity Offering Sales Agreement dated November 10, 2026, with Cantor Fitzgerald & Co.
  • ATM included in shelf: The $75,000,000 available under the sales agreement is included within, not in addition to, the $250,000,000 base shelf amount.
  • Recent share price: The last reported sale price of Ovid's common stock on November 6, 2026, was $2.85 per share, according to the filing.
  • Filer classification: The registrant identified itself as a non-accelerated filer and a smaller reporting company, and indicated it is not an emerging growth company.
  • Listing: Common stock is listed on The Nasdaq Capital Market under the symbol "OVID" (NASDAQ:OVID).

Ovid Therapeutics Registers Mixed Securities Shelf and ATM Sales Agreement

Ovid Therapeutics Inc., headquartered at 441 Ninth Avenue, 14th Floor, New York, New York 10001, filed a Form S-3 registration statement on November 10, 2026. According to the filing, the registration statement contains two components: a base prospectus and a sales agreement prospectus. The base prospectus covers the potential offering, issuance, and sale of up to $250,000,000 of common stock, preferred stock, debt securities, and/or warrants, which may be sold from time to time in one or more offerings at prices and on terms to be specified in future prospectus supplements.

The sales agreement prospectus covers up to $75,000,000 of common stock that may be issued and sold from time to time under a Controlled Equity Offering Sales Agreement dated November 10, 2026, with Cantor Fitzgerald & Co. The filing states that the $75,000,000 available under the sales agreement prospectus is included within the $250,000,000 covered by the base prospectus. The filing further discloses that if the sales agreement is terminated and no shares are sold under it, the full $250,000,000 of securities may be sold through other offerings pursuant to the base prospectus and applicable prospectus supplements.

Margaret Alexander is identified as President and Chief Executive Officer and as the agent for service of process. The filing notes that the registration statement is subject to completion and that securities may not be sold until the registration statement becomes effective. The company disclosed that investing in its securities "involves a high degree of risk" and directed prospective investors to the Risk Factors section of any applicable prospectus supplement and documents incorporated by reference. The registrant indicated it has elected to comply with reduced public company reporting requirements available to smaller reporting companies.

What Was Disclosed

Ovid Therapeutics filed a Form S-3 shelf registration on November 10, 2026, registering up to $250,000,000 in mixed securities and establishing a $75,000,000 at-the-market common stock facility with Cantor Fitzgerald & Co. under a sales agreement of the same date.